The IκB kinase (IKK) complex is the signal integration hub for NF-κB activation. Composed of two serine-threonine kinases (IKKα and IKKβ) and the regulatory subunit NEMO (also known as IKKγ), the IKK complex integrates signals from all NF-κB activating stimuli to catalyze the phosphorylation of various IκB and NF-κB proteins, as well as of other substrates. Since the discovery of the IKK complex components about 15 years ago, tremendous progress has been made in the understanding of the IKK architecture and its integration into signaling networks. In addition to the control of NF-κB, IKK subunits mediate the crosstalk with other pathways, thereby extending the complexity of their biological function. This review summarizes recent advances in IKK biology and focuses on emerging aspects of IKK structure, regulation and function.
response. However, in addition, NF-κB pathways contribute to cell adhesion, differentiation, proliferation, autophagy, senescence and protection against apoptosis. In line with its multilayered physiological functions, deregulated NF-κB activity is found in a number of disease states, including cancer, arthritis, chronic inflammation, asthma, neurodegenerative diseases, and heart disease (1, 2).
The NF-κB family consists of NFKB1 (p50/p105), NFKB2 (p52/p100), RelA (p65), c-Rel and RelB, which form various homo-and heterodimers. In resting cells, NF-κB dimers are sequestered in the cytoplasm through interaction with IκB proteins (IκBα, IκBβ and IκBε) or the precursor proteins p100 and p105. Induction of NF-κB depends on the phosphorylation of IκBs on critical serine residues. As a consequence, IκBs are ubiquitinated by the E3 ubiquitin ligase SCF βTrCP and degraded by the proteasome, which in turn allows the nuclear translocation of NF-κB heterodimers ( Fig. 1 ) (3, 4) . NF-κB precursors are -constitutively or in a stimulus dependent manner -processed by the proteasome to produce the mature transcription factors p50 and p52 (5) . As the small IκBs, p105 can undergo signal dependent phosphorylation and degradation, which frees p50 homodimers, leading to the formation of Bcl-3:p50 complexes (6) .
The discovery of the phosphorylation-dependent NF-κB activation mechanism initiated the search for an IκB kinase (IKK). An initial biochemical study described a high molecular weight kinase complex of approximately 700 kDa, which required non-degradative ubiquitination for its activity (7) . However, the identity of the kinase was not revealed. The serine/threonine kinases IKKα (85 kDa; also known as IKK1 or CHUK) and IKKβ (87 kDa; also known as IKK2), were then identified as the two catalytic components of the IKK complex, which form dimers and are able to phosphorylate IκBs in vitro (8) (9) (10) (11) (12) (13) . As a third component, NEMO (48-kDa; also known as IKKγ, IKKAP1 or Fip-3), was identified by complementation of an NF-κB unresponsive cell line and by sequencing of IKK-associated polypeptides (14, 15) . NEMO is a regulatory non-enzymatic scaffold protein. Gene ablation studies of the IKK subunits then revealed that NF-κB activation is achieved alternatively through the mechanistically different canonical and non-canonical pathways.
Inflammatory cytokines, radiation, stress signals and pathogenic assaults evoke the rapid canonical pathway and generally involve ubiquitin mediated complex formation of signaling molecules, ultimately resulting in phosphorylation of two serine residues located in the IKKα and β activation loops, similar to the activation of many other kinases ( Fig. 1 and 2 ).
Canonical signaling strictly depends on NEMO, while the catalytic subunits seem to be more redundant (16) .
The non-canonical pathway is activated by a restricted group of stimuli, such as the TNF family members lymphotoxin-α/β, BAFF or CD40L, which trigger posttranslational stabilization of NF-κB interacting kinase (NIK) (Fig. 2) . Crystal structural analysis showed that the kinase domain of NIK adopts an intrinsically active conformation, so that downstream targets can be phosphorylated without requiring an additional phosphorylation step (17) . In unstimulated cells, a TRAF-cIAP complex catalyzes K48-linked ubiquitination of NIK, leading to constitutive NIK degradation. Ligand binding induces recruitment of the TRAFcIAP complex to the receptor, whereupon TRAF2-mediated, K63-linked ubiquitination of cIAP1 ⁄ 2 switches its K48 ubiquitin ligase activity from NIK to TRAF3. The ensuing TRAF3 degradation destabilizes the TRAF-cIAP complex and enables the accumulation of newly synthesized NIK (18, 19) . NIK is thought to phosphorylate IKKα, which in turn phosphorylates and marks p100 for C-terminal processing to generate p52-containing complexes, primarily p52/RelB. The non-canonical pathway is characterized by a distinctive slower kinetics, requires neither IKKβ nor NEMO and plays a critical role in the development of lymphoid organs (20). Attenuation of the non-canonical NF-κB pathway is controlled through the DUB OTUD7B, which deubiquitinates TRAF3 in a K48-directed manner (21).
The substrate spectrum of the IKK complex is not restricted to IκBs and precursors, but includes a wide range of NF-κB pathway inherent (such as RelA) and extraneous (such as p53 and TCS1) substrates (Table 1) . Thus, the IKK complex is both a signaling hub for NF-κB activation and an interface for crosstalk between NF-κB activating pathways and other physiological processes (16, 22) .
Despite the steady increase in IKK related publications, important questions still remain unanswered (Sidebar A). How a signaling cascade mechanistically induces the activation of the IKK complex, how IKK activity is turned off and how substrate specificity is achieved has to be resolved. Recent genetic, biochemical and structural data have shed new light on IKK structure, regulation and function.
IKK complex -structures and composition
IKK-mediated activation of NF-κB is differentially regulated by IKKα and IKKβ. Both kinases have high sequence homology (approximately 50 % identity), and contain an Nterminal kinase domain, a dimerization domain and a C-terminal NEMO-binding domain (NBD) (16, 22, 23) (Fig. 3A) , although only IKKα has a predicted NLS (24). Kinase activity critically depends on lysine 44 and phosphorylated T-loop serines -S176 and 180 for IKKα, S177 and 181 for IKKβ (9) (10) (11) (12) 25) . IKKβ contains a conserved ubiquitin-like domain (ULD), which is critical for its catalytic activation (26). Much-anticipated 3D structural information was obtained in the last few years that allowed further elucidation of IKK structure-function relationships ( Table 2) .
IKK structures reveal complex intra-and inter-molecular interactions
As a major breakthrough, the long-awaited crystal structures of IKKβ were recently presented, revealing the domain organization of this catalytic IKK subunit and shedding new light on protein-protein interactions, mechanisms of activation and the mechanism of substrate recognition (27-29). IKKβ has a trimodular structure, comprising the N-terminal kinase domain (KD), a central ULD and an elongated α-helical scaffold/dimerization domain (SDD) at the C-terminus ( Fig. 3B and Table 2 ). Neither of the previously predicted LZ and HLH motifs form as these residues are part of the SDD. Notably, the IKK-related kinase 
Structural insights into NEMO
Important structural information has been obtained for NEMO. On the basis of biochemical assays, NEMO had been predicted to be a mainly α-helical protein containing two coiled-coil domains (CC), a LZ and a C-terminal zinc-finger (ZF) region (Fig. 3A) Taken together, tremendous progress has been made in understanding the structures of the IKK components, which provides the basis to finally understand the dynamic architecture of the IKK complex. Notably, although the tripartite IKK structure is perhaps the most abundant form, other IKK complexes might exist. In fact, co-expression experiments and in vitro studies have shown that NEMO can interact with IKK1 or IKK2 homodimers (54, 55) . It is a temping assumption that different complex compositions might be required for tissue specific or stimulus specific NF-κB dependent and independent signaling events. Likewise, NIKdependent activation of the non-canonical NF-κB pathway was proposed to occur through phosphorylation of IKKα homodimers (57) . However, whether specific IKK complexes with distinct oligomeric compositions and functions exist in cells remains to be demonstrated.
IKK activation and inhibition
IKKs are activated by a plethora of agents and conditions, including extracellular ligands that bind membrane receptors, such as TNFR, TLR, or IL-1R intracellular stress, such as DNA damage and reactive oxygen species, as well as the recognition of intracellular pathogens mediated by the NOD and RIG-I-like (NLR) family of proteins (Fig. 2) . The activated receptor structures nucleate dynamic regulatory networks, where protein phosphorylation, non-degradative ubiquitination, adapter protein interactions and most likely higher order oligomerization events all contribute to IKK activation ( Fig. 1 and 2 ). Moreover, canonical and non-canonical NF-κB signaling pathways can be activated by human oncogenic viruses, including the human T cell leukemia virus type 1, the Kaposi sarcoma-associated herpesvirus, and the Epstein-Bar virus (58) . Recent findings indicate that the virus encoded oncoproteins either use components of the IKK upstream signaling network or directly act on the IKK complex to activate NF-κB (59, 60) .
IKK phosphorylation
How signal transmission results in the phosphorylation of the IκB kinase T-loop is still an important unsolved question. In analogy to other signaling pathways, IKK kinases (IKKKs)
have been suggested to mediate it. A prominent example is TAK1, which is also engaged in the JNK pathway. TAK1, together with the adaptor proteins TAB1 and TAB2, was found to act as TRAF6-regulated IKK activator in cell-free assays (61, 62) . TAB2 can recruit TAK1 to K63-linked polyubiquitin chains of upstream regulators which most likely cause inducedproximity driven IKKβ phosphorylation. However, TAK1 is not an essential general IKKK, but rather a regulatory module with a stimulus and cell-type specific impact on IKK activation (16, 42) . MEKK3 was proposed as another potential IKKK, as the kinase can phosphorylate IKK in vitro and NF-κB activation is reduced in MEKK3 deficient cells in response to TNF, IL-1 or TLR stimulation (63, 64) . IL-1-induced NF-κB activation has been proposed to involve MEKK3 in addition to TAK1 (65, 66) . However, IKK subunits could also be activated by trans-autophosphorylation, as previously proposed (67), instead of through an IKKK. This latter possibility is supported by recent structural and composition analyses, as discussed above. Trans-autophosphorylation and IKKK-dependent phosphorylation could even operate successively or in parallel to reach maximum kinase activation (Fig. 1) .
Ubiquitin dependent signaling
The activation of the IKKs appears to depend on the induced proximity resulting from the dense organization of signaling complexes and on binding of adapter proteins, such as NEMO or TAB proteins. Non-degradative polyubiquitination, a crucial prerequisite of IKK complex activation, triggers both processes ( Fig. 1) (42, 43) .
In contrast to IL1β, TNFα signaling does not depend on K63-linked ubiquitination, indicating that alternative forms of non-degradative polyubiquitination are important in this pathway (70) . Accordingly, linear, M1-linked ubiquitination of NEMO and RIP1, which is catalyzed by the LUBAC complex, has been shown to be important for NF-κB activation (71, 72) . This E3 complex, consisting of HOIL1, HOIP and SHARPIN, is recruited to the TNFR1 signaling complex in a TRADD, TRAF2 and cIAP1/2 dependent manner. Furthermore, LUBAC mediated M1-linked ubiquitination contributes to IL1R, CD40, TACI, parkin and DNA damage mediated NF-κB activation, but is dispensable for B-cell receptor-mediated signaling (43, (73) (74) (75) . The physiological relevance of LUBAC was first demonstrated in mice with chronic proliferation dermatitis (Cpdm), which results from a spontaneous null mutation in the Sharpin gene. These mice mimic part of a phenotype of patients suffering X-linked hyper IGM syndrome and hypohydrotic ectodermal dysplasia, which is caused by NEMO mutations, and Cpdm-derived cells display attenuated TNF, CD40 ligand and IL1β signaling (71, 76, 77) . Biallelic inactivating mutations in HOIL1 have been identified in patients suffering an inherited disorder with immunodeficiency, autoinflammation and amylopectinosis (78) .
HOIL1 deficiency and subsequent LUBAC destabilization resulted in impaired NF-κB-mediated IL1β responses, which differed depending on the tissue (78) . Thus, the ubiquitin linkage type seems not only to confer stimulus-specific, but also cell type-specific restraints in NF-κB activation.
There is accumulating evidence that alternative and even hybrid ubiquitin linkages play a role in NF-κB signaling, thereby increasing the complexity of ubiquitin-mediated processes (43) .
In vitro assays have demonstrated that the E3 ligases cIAP1 and TRIM23 can catalyze K6-linked or K27-linked polyubiquitination of NEMO, respectively (79, 80) . Modification of RIP1 seems to be a special case, because TNFα treatment induces modification with degradative K48 as well as with non-degradative M1-, K63-, and K11-linked ubiquitin chains (47, 71, (81) (82) (83) . The fact that only one ubiquitin acceptor site (K377) has been determined until now (81) , raises the question, of whether TNFα induces distinct populations of modified RIP1 or, alternatively, the modification of RIP1 with a poly-ubiquitin chain containing mixed linkages. Indeed, an analogous process has been recently reported for IRAK1, IRAK4 and MYD88, which are modified with K63/M1-linked hybrid ubiquitin chains in IL1R or TLR stimulated cells (52) . In addition to polyubiquitin, monoubiquitination of proteins has a functional impact (84) . In fact, a modified NEMO species 8 kDa larger, which most likely indicates a mono-ubiquitinated form, is generated in cells stimulated with various agents (68, 72, 85, 86) . K285 could be determined as the acceptor site using mass spectrometry and mutational analysis (68, 85) . The same site, in addition to K309, was determined as acceptor for M1-linked ubiquitination (72) . Site-specific ubiquitination of NEMO was shown to be crucial for NF-κB activation in both cell culture and in a mouse model (68, 72, 85, 87) . Thus, IKK activation coincides with two parallel or sequentially occurring modifications of NEMO.
As Taken together, oligomerization appears to occur at all levels of canonical signaling cascades, in which multiple signaling oligomers combine to perform multiple reactions simultaneously and efficiently. The clustering of signaling molecules is an attractive mechanism that could provide temporal and spatial control of signal transmission and might help to increase the signal-to-noise ratio (92) . Therefore, a focus of future research should be to prove whether higher-order assemblies of signaling molecules are a general feature of canonical and even non-canonical NF-κB signaling.
Control of transience and attenuation of IKK activity by feedback regulation
To maintain the transient nature of NF-κB activity, signal transmission is controlled by various levels of negative feedback mechanisms, including direct regulation of IKK as well as negative feedback mechanisms that affect upstream signaling components ( SUMOylation of NEMO is a critical step in the response to DNA double strand breaks.
Amongst the Sentrin/SUMO-specific proteases (SENPs), SENP2 has been shown to specifically deSUMOylate NEMO and attenuate NF-κB activation. Since NF-κB promotes SENP2 expression, a negative feedback loop is established (107) .
IKK functions
Although the tripartite structure of the IKK complex suggests common physiological roles for IKKα, IKKβ and NEMO, the phenotypes of the single knockouts suggest they have common, but also distinct functions. IKKβ deficient mice are embryonically lethal and die, like p65 deficient mice, at embryonic day 13, primarily due to TNF-induced liver apoptosis. These results underscore the importance of IKKβ in canonical NF-κB signaling (108, 109) .
However, subsequent studies with IKKβ deficient cells indicate that the absolute requirement for IKKβ in canonical NF-κB signaling depends on the stimulus. IKKα can substitute IKKβ function at least in the case of IL-1R signaling (110) .
IKKα deficient mice can survive for a month after birth, but suffer from striking morphological defects, such as markedly hyperplasic epidermis (111) . Follow up studies determined that IKKα is a major cofactor in a TGFbeta-Smad2/3 signaling pathway that is required for cell cycle exit and induction of terminal differentiation of keratinocytes (112) .
Accordingly, IKKα has been shown to be a critical suppressor of skin cancer in humans and mice (113, 114) . In addition to its specific function in TGF-β mediated keratinocyte differentiation, IKKα is a crucial regulator of non-canonical NF-κB signaling, required for B cell maturation and formation of secondary lymphoid organs (57) . It is also involved in the maturation of dendritic cells and pancreatic homeostasis (115, 116) . IKKβ dependent phosphorylation of p65 on Ser536 enhances its transactivation potential, while IKKα mediated c-terminal phosphorylation of p65 and c-Rel attenuates their activity (118, 119) . However, IKKα has been shown to accumulate in the nucleus in a stimulus dependent manner and to phosphorylate chromatin components (Table 1) , implicating a more far-ranging spectrum of biological functions (16) . There is ample evidence that IKK activity is not restricted to NF-κB dependent pathways but can also mediate cross-talk with other signaling cascades, such as mTOR and MAPK pathways (1, 16, 120 Taken together, a number of IKK substrates have been identified, which also have revealed the enormous complexity of IKK function in (patho)biology (Table 1) . In many cases, the detailed regulatory mechanisms are still elusive and there are questions regarding substrate specificity and the nature of the signaling outcome depending on the stimulus, tissue and environment. Moreover, cell-type specific variations in IKK expression levels and altered IKK complex composition might contribute to specific functions.
Concluding remarks and perspectives
Our understanding of the impact that IKK/NF-κB signaling has in mammalian physiology and pathophysiology is continuously growing, as the number of diseases with an involvement of the IKK/NF-κB system steadily increases. IKK/NF-κB signaling has also been shown to be one of the key mediators in aging (150) . As an example, hypothalamic programming of systemic ageing in mice depends on IKKβ and NF-κB (151) . Intriguingly, IKKα and IKKβ also trigger a wide variety of NF-κB independent signaling events, which control various physiological functions and impact disease states like cancer and diabetes (Table 1) Although the NF-κB/IKK pathway is the target of long-standing and intense research, its pharmacological intervention in human disease is still very limited. Given that IKK is involved in numerous physiological processes, it will be important to target the specific upstream modules that control IKK activation in response to particular signals or conditions.
However, the design of such a pathway-tailored therapy requires a complete and detailed knowledge of the mechanisms that control IKK activation. 
